To the full analysis
Buyback calculator for Neurocrine Biosciences
Neurocrine Biosciences stock: key metrics
NBIXNeurocrine Biosciences had an operating margin of 21.6% and a return on invested capital (ROIC) of 20.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 0.0% | −288.8% | −273.2% |
| 2007 | 0.0% | −17,340.0% | −16,936.2% |
| 2008 | 100.0% | −2,196.2% | −2,229.3% |
| 2009 | 100.0% | −1,817.5% | −1,728.3% |
| 2010 | 100.0% | −41.0% | −23.8% |
| 2011 | 100.0% | 43.8% | 48.5% |
| 2012 | 0.0% | 2.7% | 9.5% |
| 2013 | 0.0% | −1,701.9% | −1,579.0% |
| 2014 | no data | no data | no data |
| 2015 | 100.0% | −476.5% | −449.8% |
| 2016 | 100.0% | −982.5% | −940.6% |
| 2017 | 99.2% | −81.3% | −88.2% |
| 2018 | 98.9% | 8.2% | 4.7% |
| 2019 | 99.1% | 9.2% | 4.7% |
| 2020 | 99.0% | 15.6% | 38.9% |
| 2021 | 98.7% | 9.0% | 7.9% |
| 2022 | 98.4% | 16.7% | 10.4% |
| 2023 | 97.9% | 13.3% | 13.2% |
| 2024 | 98.6% | 24.2% | 14.5% |
| 2025 | 98.2% | 21.6% | 16.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −34.1% | −48.2% | −27.5% |
| 2007 | −100.0% | −53.9% | −74.9% |
| 2008 | −100.0% | −39.6% | −75.0% |
| 2009 | −100.0% | −54.7% | −72.1% |
| 2010 | −41.2% | −14.8% | −5.5% |
| 2011 | 62.5% | 37.1% | 27.2% |
| 2012 | 3.3% | 1.1% | 2.6% |
| 2013 | −38.3% | −24.3% | −29.8% |
| 2014 | −29.0% | −27.5% | −24.9% |
| 2015 | −21.0% | −22.0% | −18.7% |
| 2016 | −44.8% | −29.7% | −38.6% |
| 2017 | −38.3% | −88.9% | −17.4% |
| 2018 | 4.4% | 16.0% | 2.1% |
| 2019 | 5.8% | 16.9% | 2.8% |
| 2020 | 36.2% | 27.2% | 23.5% |
| 2021 | 6.5% | 9.8% | 4.3% |
| 2022 | 9.0% | 17.3% | 6.5% |
| 2023 | 11.2% | 14.5% | 7.7% |
| 2024 | 13.2% | 22.3% | 9.2% |
| 2025 | 14.7% | 20.2% | 10.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.